Kairos Pharma Ltd. (NYSE American: KAPA) announced its participation in the DealFlow Discovery Conference scheduled for January 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. The company's Chief Scientific Officer, Neil Bhowmick, will deliver a company presentation and conduct one-on-one meetings with investors during the event. This participation comes as Kairos continues to advance its clinical-stage oncology programs, positioning the company to engage with the investment community at a critical juncture in its development.
The conference appearance underscores Kairos Pharma's focus on oncology therapeutics, particularly its utilization of structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types, addressing a significant challenge in oncology treatment.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. These trials are aimed at addressing unmet medical needs in cancer care. It is important to note that, as of the press release date, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any comparable foreign regulator. Investors and industry observers can access the latest news and updates relating to KAPA in the company's newsroom at https://ibn.fm/KAPA.
The DealFlow Discovery Conference provides a platform for Kairos Pharma to communicate its progress and strategy directly to investors. For business and technology leaders, this development highlights the ongoing innovation in biotechnology, particularly in addressing complex issues like drug resistance in cancer. The advancement of therapies such as ENV-105 could have broader implications for the healthcare industry, potentially improving treatment outcomes and reducing relapse rates in oncology patients. As Kairos Pharma moves forward with its clinical trials, its participation in events like this conference is a key step in building investor confidence and advancing its mission in cancer therapeutics.
